Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
LONDON, June 25, 2024 (GLOBE NEWSWIRE) -- Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human ...
UK-based biotechnology company Engitix Ltd. has raised a further $25 million from billionaire Michael Platt to help develop its therapies for cancer and fibrosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback